Nano Dimension Ltd. has 12 Schedule 13D or 13G filings on record since 2025-07-03. 2 holders' latest filing reports 5% or more of ordinary shares par value nis 5.00 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Tang Capital Management, LLC | 9.1% | 19,232,538 | SCHEDULE 13G, 2026-08-21 | 2026-08-19 |
| Murchinson Ltd. | 8.1% | 17,136,276 | SCHEDULE 13D/A, 2026-07-20 | 2026-07-17 |
| Anson Funds Management LP | 4.2% | 9,057,952 | SCHEDULE 13D/A, 2025-07-14 | 2025-07-11 |
| Oramed Pharmaceuticals Inc. | 3.3% | 6,879,708 | SCHEDULE 13D/A, 2026-07-22 | 2026-07-20 |
Purpose of Transaction (Item 4)
Murchinson Ltd.
Item 4 is hereby amended to add the following: On July 17, 2026, the Reporting Persons entered into a settlement agreement (the "Settlement agreement") with the Issuer, pursuant to which (i) each of Robert Pons, David Stehlin, Dr. Joshua Rosensweig, and Andrew Sriubas (the "Departing Directors") resigned from the Issuer's board of directors (the "Board") and all positions with the Issuer, (ii) the Issuer appointed each of Pinchos (Paul) Fruchthandler, Moshe Rozenbaum and Eliezer Eli Tarlow to serve as a member of the Board as a Class I, Class II and Class III director, respectively, with an initial term expiring at the Issuer's 2026 annual general meeting of shareholders to fill the vacancies resulting from the resignations of the Departing Directors, and (iii) the Reporting Persons irrevocably withdrew their demand that the Issuer call an extraordinary general meeting of shareholders (the "EGM") to vote on various proposals submitted by such Reporting Persons, enabling the Issuer to cancel the EGM scheduled to be held on July 31, 2026. In addition, pursuant to the Settlement Agreement, the Reporting Persons, the Issuer and the Departing Directors agreed to certain litigation-related provisions, including a release of certain claims and a covenant not to initiate or pursue certain legal proceedings, as well as certain non-disparagement provisions. The foregoing description of the Settlement Agreement does not purport to be complete and is qualified in its entirety by …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-07-20; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-03 | Anson Funds Management LP | 7.5% | SCHEDULE 13D/A |
| 2025-07-14 | Anson Funds Management LP | 4.2% | SCHEDULE 13D/A |
| 2026-01-29 | Oramed Pharmaceuticals Inc. | 5% | SCHEDULE 13D |
| 2026-02-19 | Oramed Pharmaceuticals Inc. | 5.2% | SCHEDULE 13D/A |
| 2026-05-21 | Murchinson Ltd. | 7.4% | SCHEDULE 13D/A |
| 2026-06-17 | Oramed Pharmaceuticals Inc. | 7.2% | SCHEDULE 13D/A |
| 2026-06-23 | Murchinson Ltd. | 9.6% | SCHEDULE 13D/A |
| 2026-06-30 | Tang Capital Management, LLC | 6.8% | SCHEDULE 13D |
| 2026-07-20 | Murchinson Ltd. | 8.1% | SCHEDULE 13D/A |
| 2026-07-22 | Oramed Pharmaceuticals Inc. | 3.3% | SCHEDULE 13D/A |
| 2026-07-27 | Tang Capital Management, LLC | 7.9% | SCHEDULE 13D/A |
| 2026-08-21 | Tang Capital Management, LLC | 9.1% | SCHEDULE 13G |
Tools for this story
Each opens in a new tab, filled in for Nano Dimension Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.